Cargando…

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition

Detalles Bibliográficos
Autores principales:	Alicke, Bruno, Varfolomeev, Eugene, Lee, Shi Hui Kaylee, Frommlet, Alexandra, Ubhayakar, Savita, Quinn, John G., Fairbrother, Wayne J., Jones, Robert, Gould, Stephen E., Vucic, Domagoj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519744/ https://www.ncbi.nlm.nih.gov/pubmed/36171193 http://dx.doi.org/10.1038/s41419-022-05283-w

Ejemplares similares

Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021)

DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
por: Thibault, Benoît, et al.
Publicado: (2018)

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
por: Bellaye, Pierre-Simon, et al.
Publicado: (2018)

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

IAP Workshop
Publicado: (1996)

Effects of Physiological and Synthetic IAP Antagonism on c-IAP-Dependent Signaling
por: Kocab, Andrew J., et al.
Publicado: (2015)

Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist
por: Udompholkul, Parima, et al.
Publicado: (2023)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

IAP textbook of vaccines
por: Kabra, S. K.
Publicado: (2016)

IAPS Presidential Address
por: Ramadwar, Ravindra
Publicado: (2022)

The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020)

IAP-IAP Complexes Required for Apoptosis Resistance of C. trachomatis–Infected Cells
por: Rajalingam, Krishnaraj, et al.
Publicado: (2006)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
por: Liu, Xin, et al.
Publicado: (2022)

The expanding role of IAP antagonists for the treatment of head and neck cancer
por: Kansal, Vikash, et al.
Publicado: (2023)

IAP Display: A Simple Method to Identify Mouse Strain Specific IAP Insertions
por: Ray, Akshay, et al.
Publicado: (2010)

c-IAP1 and c-IAP2 Redundancy Differs between T and B Cells
por: Giardino Torchia, Maria Letizia, et al.
Publicado: (2013)

Drosophila IAP antagonists form multimeric complexes to promote cell death
por: Sandu, Cristinel, et al.
Publicado: (2010)

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Development of Peptidomimetics Targeting IAPs
por: Sharma, Sushil K., et al.
Publicado: (2006)

Development of rebunching cavities at IAP
por: Welsch, C P, et al.
Publicado: (2000)

IAPS Textbook of Pediatric Surgery
por: Jacobsen, Anette
Publicado: (2020)

IAPS Textbook of Pediatric Surgery
por: Raffensperger, John G.
Publicado: (2020)

Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
por: Darding, M, et al.
Publicado: (2011)

Intestinal alkaline phosphatase (IAP, IAP Enhancer) attenuates intestinal inflammation and alleviates insulin resistance
por: Gao, Chenzhe, et al.
Publicado: (2022)

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
por: Langdon, Casey G., et al.
Publicado: (2015)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
por: Hurwitz, Herbert I., et al.
Publicado: (2015)

5th IAP Astrophysics Meeting
por: Audouze, Jean, et al.
Publicado: (1990)

3rd IAP Astrophysics Meeting
por: Bergeron, Jacqueline, et al.
Publicado: (1987)

2nd IAP Astrophysics Meeting
por: Audouze, Jean, et al.
Publicado: (1986)

Layout of an Electrostatic Storage Ring at IAP
por: Welsch, C P, et al.
Publicado: (2001)

Regulation of Apoptosis by Inhibitors of Apoptosis (IAPs)
por: Berthelet, Jean, et al.
Publicado: (2013)

Targeting IAP proteins in combination with radiotherapy
por: Fulda, Simone
Publicado: (2015)

The abstracts of IAP meetings will not be covered in JAPID
por: Shirmohammadi, Adileh
Publicado: (2020)

Bidding Adieu to IAP Year 2022
por: Remesh Kumar, R
Publicado: (2022)

Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination
por: de Almagro, M C, et al.
Publicado: (2015)

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
por: Yang, Chengcheng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cr91n248j74furp2qh6q35sn5p